TCRX
TScan Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.39
+5.55%Next report
Analyst consensus
- Next report date
- Nov 11, 2026
- EPS estimate
- -$0.30
- Revenue estimate
- $1.1M
Latest reported
- Last report date
- Aug 12, 2026
- EPS actual
- -$0.23
- EPS estimate
- -$0.25
- Revenue actual
- $1.1M
- Revenue estimate
- $1.9M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 2
- Avg surprise (4Q)
- +15.6%
- Revenue beats (12Q)
- 5
Analyst ratings
Sell-side consensus
- Consensus
- Hold
- Price target
- $4.67
- PT range
- $1.00 – $7.00
- Analysts
- 3
1 Buy2 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026